A Phase 1 interventional study of Baricitinib and Omeprazole in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to find out how the body will react to a study drug called baricitinib when taken with another drug called omeprazole.
For each participant, this study will include 2 periods in fixed order. The study will last approximately 25 days, not including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Baricitinib - 10 milligram (mg) tablet administered orally, once, on Day 1.
Drug: Baricitinib
Baricitinib - 10 mg tablet administered orally, once, on Day 10. Omeprazole - 40 mg capsule administered orally once daily (QD) for 8 days (Days 3 through 10).
Drug: Baricitinib · Drug: Omeprazole
Administered orally
Also known as: LY3009104
Administered orally
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib
Time frame: Days 1 and 10: predose of baricitinib, 0.5, 0.75, 1, 2, 3, 4, 6, 12, 24, 36 and 48 hours postdose
PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib
Time frame: Days 1 and 10: predose of baricitinib, 0.5, 0.75, 1, 2, 3, 4, 6, 12, 24, 36 and 48 hours postdose
PK: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Baricitinib
Time frame: Days 1 and 10: predose of baricitinib, 0.5, 0.75, 1, 2, 3, 4, 6, 12, 24, 36 and 48 hours postdose
| Milestone | Baricitinib + Omeprazole |
|---|---|
| Started | 30 |
| Received baricitinib | 30 |
| Completed | 30 |
| Not completed | 0 |
| Milestone | Baricitinib + Omeprazole |
|---|---|
| Started | 30 |
| Received baricitinib | 30 |
| Received 8 doses of omeprazole | 30 |
| Completed | 30 |
| Not completed | 0 |
| nanograms/milliliter (ng/mL) | Baricitinib | Baricitinib + Omeprazole |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib | 99.2 ± 32 | 76.8 ± 25 |
| hours | Baricitinib | Baricitinib + Omeprazole |
|---|---|---|
| PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib | 1.00 (0.50 to 3.00) | 2.00 (0.75 to 6.00) |
| nanograms*hour/milliliter (ng*h/mL) | Baricitinib | Baricitinib + Omeprazole |
|---|---|---|
| PK: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Baricitinib | 663 ± 23 | 712 ± 23 |
Collected over Baseline through study completion (up to Day 24).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baricitinib | — | 0/30 (0%) | 5/30 (16.7%) |
| Omeprazole | — | 0/30 (0%) | 8/30 (26.7%) |
| Baricitinib + Omeprazole | — | 0/30 (0%) | 7/30 (23.3%) |
| Event | Baricitinib | Omeprazole | Baricitinib + Omeprazole |
|---|---|---|---|
| HeadacheNervous system disorders | 4/30 | 3/30 | 6/30 |
| DiarrhoeaGastrointestinal disorders | 0/30 | 4/30 | 2/30 |
| Abdominal pain upperGastrointestinal disorders | 0/30 | 3/30 | 0/30 |
| FlatulenceGastrointestinal disorders | 1/30 | 2/30 | 0/30 |
| NauseaGastrointestinal disorders | 2/30 | 1/30 | 0/30 |
All enrolled participants.
| Age, Continuous(years) | Baricitinib + Omeprazole |
|---|---|
| Mean | 44.1 ± 14.1 |
| Sex: Female, Male(Participants) | Baricitinib + Omeprazole |
|---|---|
| Female | 8 |
| Male | 22 |
| Ethnicity (NIH/OMB)(Participants) | Baricitinib + Omeprazole |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 30 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Baricitinib + Omeprazole |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 29 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Baricitinib + Omeprazole |
|---|---|
| United Kingdom | 30 |
The record gives a start of Oct 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib